Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)

The summary for the Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional): Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips are fast, sensitive, low cost and reasonably accurate. However, as there might not be testing strips for the new threats, the analysis must be performed via sensitive and sample agnostic methods.
Federal Grant Title: Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education, Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-26-019
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Information not provided
Current Application Deadline: February 19th, 2025
Original Application Deadline: February 19th, 2025
Posted Date: November 4th, 2024
Creation Date: November 4th, 2024
Archive Date: March 27th, 2025
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: November 4th, 2024
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following: See NOFO for further Eligibility Requirements.
Link to Full Grant Announcement
https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html
Grant Announcement Contact
NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants
Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R41 - Cl...
Medical Devices for Pediatric Population Affected by Substance Use and Addiction (R43 - Cl...
Limited Competition: NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinic...
NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial O...
Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleter...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
Alcohol Health Services Research (R01 Clinical Trial Optional)
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)
Effectiveness Trials to Test Mental Health System Interventions (R61/R33 Clinical Trial Re...
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com